Alvotech Reveals Positive Data For Stelara Rival

Results For AVT04 Ustekinumab Biosimilar Come Ahead Of Oaktree SPAC Merger Vote

 
• By David Wallace
  
$9bn nine billion dollars yellow icon
Stelara represents a $9bn target for Alvotech • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products